Bionomics Expands Aussie Phase II Trials For Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Australia's Bionomics says it has added a dozen new sites for conducting Phase II trials of its BNC105 drug for treating mesothelioma, a lung cancer often caused by exposure to asbestos
You may also be interested in...
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Merz Consumer Care Optimistic About Future As German Lockdown Continues
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
Towa Plans 10 Launches In December 2020
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Need a specific report? 1000+ reports available
Buy Reports